Trial Profile
A Phase II Study of TARCEVA (erlotinib) in Combination with Chemoradiation in Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Apr 2019 Status changed from active, no longer recruiting to completed.
- 02 Feb 2018 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 02 Feb 2018 Planned primary completion date changed from 1 May 2017 to 1 May 2019.